UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: A study of the Princess Margaret Hospital Phase II consortium

Gynecologic Oncology

Volumn 106, Issue 2, 2007, Pages 305-310

  Welch, Stephen ^a   Hirte, Hal W ^b   Carey, Mark S ^c   Hotte, Sebastian J ^b   Tsao, Ming Sound ^a   Brown, Shirley ^a   Pond, Gregory R ^a   Dancey, Janet E ^d   Oza, Amit M ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b JURAVINSKI CANCER CENTRE   (Canada)

^c LONDON REGIONAL CANCER PROGRAM   (Canada)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cyclin dependent kinase modulator; Ovarian cancer; Topotecan; UCN 01

Indexed keywords

7 HYDROXYSTAUROSPORINE; PACLITAXEL; PLATINUM; TOPOTECAN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER FATIGUE; CANCER GRADING; CANCER GROWTH; CANCER PAIN; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERGLYCEMIA; INFECTION; LYMPHOCYTOPENIA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; THROMBOCYTOPENIA; TREATMENT DURATION; TUMOR BIOPSY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; STAUROSPORINE; TOPOTECAN;

EID: 34547094373     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.02.018     Document Type: Article

References (24)

1. Creemers G.J., Bolis G., Gore M., Scarfone G., Lacave A.J., Guastalla J.P., et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J. Clin. Oncol. 14 (1996) 3056-3061
2. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., and Lacave A.J. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 19 (2001) 3312-3322
3. ten Bokkel Huinink W., Gore M., Carmichael J., Gordon A., Malfetano J., Hudson I., et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol. 15 (1997) 2183-2193
4. Del Bino G., Lassota P., and Darzynkiewicz Z. The S-phase cytotoxicity of camptothecin. Exp. Cell Res. 193 (1991) 27-35
5. Takahashi I., Saitoh Y., Yoshida M., Sano H., Nakano H., Morimoto M., et al. UCN-01 and UCN-02, new selective inhibitors of protein kinase C: II. Purification, physico-chemical properties, structural determination and biological activities. J. Antibiot. (Tokyo) 42 (1989) 571-576
6. Akinaga S., Nomura K., Gomi K., and Okabe M. Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cells. Cancer Chemother. Pharmacol. 33 (1994) 273-280
7. Graves P.R., Yu L., Schwarz J.K., Gales J., Sausville E.A., O'Connor P.M., et al. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J. Biol. Chem. 275 (2000) 5600-5605
8. Busby E.C., Leistritz D.F., Abraham R.T., Karnitz L.M., and Sarkaria J.N. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res. 60 (2000) 2108-2112
9. Husain A., Yan X.J., Rosales N., Aghajanian C., Schwartz G.K., and Spriggs D.R. UCN-01 in ovary cancer cells: effective as a single agent and in combination with cis-diamminedichloroplatinum(II)independent of p53 status. Clin. Cancer Res. 3 (1997) 2089-2097
10. Monks A., Harris E.D., Vaigro-Wolff A., Hose C.D., Connelly J.W., and Sausville E.A. UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines. Invest. New Drugs 18 (2000) 95-107
11. Tse A.N., and Schwartz G.K. Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe. Cancer Res. 64 (2004) 6635-6644
12. Shao R.G., Cao C.X., Shimizu T., O'Connor P.M., Kohn K.W., and Pommier Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res. 57 (1997) 4029-4035
13. Dees E.C., Baker S.D., O'Reilly S., Rudek M.A., Davidson S.B., Aylesworth C., et al. A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors. Clin. Cancer Res. 11 (2005) 664-671
14. Kortmansky J., Shah M.A., Kaubisch A., Weyerbacher A., Yi S., Tong W., et al. Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. J. Clin. Oncol. 23 (2005) 1875-1884
15. Lara Jr. P.N., Mack P.C., Synold T., Frankel P., Longmate J., Gumerlock P., et al. The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. Clin. Cancer Res. 11 (2005) 4444-4450
16. Hotte S.J., Oza A., Winquist E.W., Moore M., Chen E.X., Brown S., et al. Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study. Ann. Oncol. 17 (2006) 334-340
17. Simon R. Optimal two-stage designs for phase II clinical trials. Control. Clin. Trials 10 (1989) 1-10
18. Hoskins P., Eisenhauer E., Beare S., Roy M., Drouin P., Stuart G., et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J. Clin. Oncol. 16 (1998) 2233-2237
19. Kondapaka S.B., Zarnowski M., Yver D.R., Sausville E.A., and Cushman S.W. 7-Hydroxystaurosporine (UCN-01) inhibition of Akt Thr308 but not Ser473 phosphorylation: a basis for decreased insulin-stimulated glucose transport. Clin. Cancer Res. 10 (2004) 7192-7198
20. Shah M.A., Kortmansky J., Motwani M., Drobnjak M., Gonen M., Yi S., et al. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin. Cancer Res. 11 (2005) 3836-3845
21. Schwartz G.K. Development of cell cycle active drugs for the treatment of gastrointestinal cancers: a new approach to cancer therapy. J. Clin. Oncol. 23 (2005) 4499-4508
22. Wang Q., Fan S., Eastman A., Worland P.J., Sausville E.A., and O'Connor P.M. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J. Natl. Cancer Inst. 88 (1996) 956-965
23. Yu Q., La Rose J., Zhang H., Takemura H., Kohn K.W., and Pommier Y. UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1. Cancer Res. 62 (2002) 5743-5748
24. Hirose Y., Berger M.S., and Pieper R.O. Abrogation of the Chk1-mediated G2 checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res. 61 (2001) 5843-5849